Beginning yesterday, the agency's card programme is providing increased support for colorectal cancer, lung cancer, multiple myeloma, Parkinson's disease, and thyroid disease.

Source: https://jamaica-star.com/article/news/20231026/five-new-health-conditions-added-nhf-card-programme

GC012F is currently being studied in multiple investigator-initiated trials (IIT) evaluating its safety and efficacy in RRMM, newly-diagnosed multiple myeloma, and B-cell non-Hodgkin's lymphoma.

Source: https://www.marketscreener.com/quote/stock/GRACELL-BIOTECHNOLOGIES-I-117317674/news/Gracell-Biotechnologies-Announces-FDA-Clearance-of-the-IND-Application-for-Phase-1b-2-Clinical-Trial-42890341/?utm_medium=RSS&utm_content=20230203

Turning to Slide 14, our GPRC5D targeting CAR-T is a potential first-in-class agent in relapse or refractory multiple myeloma.

Source: https://seekingalpha.com/article/4609793-bristol-myers-squibb-company-bmy-presents-2023-virtual-asco-investor-event-conference?source=feed_all_articles